Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

Jake Lerch, The Motley Fool

Sat, July 11, 2026 astatine 1:05 PM CDT 6 min read

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad-based vulnerability to the healthcare assemblage astatine little costs and little volatility, portion the Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) offers focused vulnerability to the biotechnology subsector with higher humanities returns.

Investors seeking healthcare vulnerability indispensable take betwixt wide stableness and thematic concentration. While some the Invesco money and the SPDR money people the healthcare industry, they disagree importantly successful sub-sector tilts, disbursal ratios, and humanities volatility, making them suitable for antithetic portfolio roles.

Snapshot (cost & size)

Beta measures terms volatility comparative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr instrumentality represents full instrumentality implicit the trailing 12 months. Dividend output is the trailing-12-month organisation yield.

From a outgo perspective, the SPDR money is much than doubly arsenic businesslike arsenic the Invesco fund, which is simply a important origin for semipermanent compounding. This disbursal advantage, combined with a output astir treble that of its biotechnology peers, whitethorn entreaty to income-oriented investors.

Performance & hazard examination

What's wrong

State Street Health Care Select Sector SPDR ETF reflects the terms and output show of the Health Care Select Sector Index, maintaining a 100% tilt toward the healthcare sector. The money holds 60 stocks, and its largest positions see Eli Lilly & Co (NYSE:LLY) astatine 16.39%, Johnson & Johnson (NYSE:JNJ) astatine 10.80%, and AbbVie (NYSE:ABBV) astatine 7.61%. It was launched successful 1998. State Street Health Care Select Sector SPDR ETF has paid $2.53 per stock implicit the trailing 12 months, which, astatine its caller ~$162.17 stock price, yields 1.60%.

Invesco Nasdaq Biotechnology ETF tracks the Nasdaq Biotechnology Index, which is composed of 94% healthcare companies and 6% currency and different assets. It holds 253 stocks, and its largest positions see Vertex Pharmaceuticals (NASDAQ:VRTX) astatine 7.89%, Amgen (NASDAQ:AMGN) astatine 7.74%, and Gilead Sciences (NASDAQ:GILD) astatine 7.16%. It was launched successful 2021. Invesco Nasdaq Biotechnology ETF has paid $0.26 per stock implicit the trailing 12 months, which, astatine its caller ~$33.97 stock price, yields 0.80%.